Nanavaty Maulik
Nanavaty Maulik's purchase track record
Nanavaty Maulik has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/16/2023 | RANI | $990 | +71.7% | +175.8% | +17.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.
Transaction History
| RANI | ▲ Buy | Open Market | 500 | $990 | 11/16/2023 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,630 | $0 | 2/28/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 564 | $25K | 2/28/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,714 | $0 | 2/21/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 593 | $25K | 2/21/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,779 | $0 | 2/18/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 616 | $26K | 2/18/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 2,166 | $0 | 2/17/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 750 | $32K | 2/17/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,661 | $0 | 2/15/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 575 | $25K | 2/15/2022 | View on chart |
| RANI | ▼ Sell | Other | 11,017 | $0 | 2/3/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 6,175 | $0 | 1/1/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 2,346 | $100K | 1/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
RANI joins FDA Emerging Technology Platform
Rani Therapeutics was added to the FDA’s Emerging Technology Platform, a program that highlights innovative medical technologies. The inclusion signals that the FDA sees potential in the company’s approach and may facilitate future regulatory interactions. This development comes as the stock is trading near its recent support level.
RANI joins FDA Emerging Technology Platform. Rani Therapeutics was added to the FDA’s Emerging Technology Platform, a program that highlights innovative medical technologies. The inclusion signals that the FDA sees potential in the company’s approach and may facilitate future regulatory interactions. This development comes as the stock is trading near its recent support level.